[Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].

Q4 · MEDICINE

ArticleOA

Author: Beliaeva, S A

AIMTo study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH).MATERIAL AND METHODSA total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n=40) received proxodolol, group 2 (n=20) was given carvedilol. The trial lasted for 89 days.RESULTSThe trial demonstrates that proxodolol is highly effective and safe in the treatment of AH.CONCLUSIONProxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.

01 Jan 2011·Eksperimental'naia i klinicheskaia farmakologiia

[Effects of carvedilol and proxodolol on nitric oxide (NO) metabolism in various organs in a congestive heart failure model].

Article

Author: Vanin, A F ; Medvedev, O S ; Timoshin, A A ; Shashurin, D A

There is certain evidence that high efficacy of beta-adrenoblockers with alpha-adrenoblocking effect (vasodilating beta-blockers) in congestive heart failure (CHF) can be explained by their effect on nitric oxide (NO) metabolism. In this context, the possible effects of carvedilol and proxodolol on the NO level in different organs have been studied on CHF model. The heart failure was modeled in rats by ligation of the coronary artery. Operated animals were divided into experimental groups treated with carvedilol or proxodolol and the untreated (control) group. In addition, a group of sham-operated animals was formed. After 28 days of treatment, the NO level was measured in heart, liver, and kidneys using the EPR method with spin trap. It was found that, in carvedilol-treated group, the NO level in liver is significantly lower than in other groups, which can be explained by the inhibitory action of carvedilol on the NO metabolism in this organ. The NO levels in myocardium and kidney in the control group were higher than in the sham-operated group, which confirms previous findings that the NO levels increases in CHF. Both drugs significantly decreased the NO concentration in myocardium and kidney tissue compared to control animals.

01 Jan 2006·KardiologiiaQ4 · MEDICINE

[Efficacy and Safety of a Domestic Non-selective b-adrenoblocker Possibilities of the Use of Proxodolol in the Treatment of Patients With Chronic Heart Failure.].

Q4 · MEDICINE

Article

Author: Sizova, Zh M ; Ol'binskaia, L I

Novel (made in Russia) nonselective b-blocker with a1-blocking properties proxodolol was given to 30 patients with ischemic heart disease, NYHA class II-III chronic heart failure (CHF) and left ventricular ejection fraction (LVEF) <40%. Methods of control included clinical examination, registration of hemodynamic and morphofunctional parameters of the heart. Proxodolol caused clinical improvement which appeared as reduction of signs of CHF and betterment of myocardial contractile function with 14% increase of LVEF according to data of echocardiography. Side effects of proxodolol were noted in 26.7% of cases and required withdrawal of the preparation in 6.7% of patients.

100 Deals associated with Proxodolol

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Proxodolol

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation